According to Emergent BioSolutions
's latest financial reports the company has $0.11 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.11 B | -82.62% |
2022-12-31 | $0.64 B | 11.54% |
2021-12-31 | $0.57 B | -7.28% |
2020-12-31 | $0.62 B | 270.26% |
2019-12-31 | $0.16 B | 49.55% |
2018-12-31 | $0.11 B | -37.07% |
2017-12-31 | $0.17 B | -34.33% |
2016-12-31 | $0.27 B | -11.93% |
2015-12-31 | $0.30 B | 9.91% |
2014-12-31 | $0.28 B | 56.41% |
2013-12-31 | $0.17 B | 26.59% |
2012-12-31 | $0.14 B | -2.88% |
2011-12-31 | $0.14 B | -14.72% |
2010-12-31 | $0.17 B | 66.19% |
2009-12-31 | $0.10 B | 12.52% |
2008-12-31 | $91.47 M | -13.48% |
2007-12-31 | $0.10 B | 38.36% |
2006-12-31 | $76.41 M | 110.55% |
2005-12-31 | $36.29 M | 432.09% |
2004-12-31 | $6.82 M | |
2002-12-31 | $4.89 M | -16.45% |
2001-12-31 | $5.85 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 11,260.79% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 6,250.04% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $6.35 B | 5,589.19% | ๐ฌ๐ง UK |
Soligenix SNGX | $8.44 M | -92.44% | ๐บ๐ธ USA |
SIGA Technologies SIGA | $0.15 B | 34.42% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $0.42 B | 279.23% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $3.22 B | 2,788.09% | ๐ฎ๐ฑ Israel |